Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-30T21:46:41.513Z Has data issue: false hasContentIssue false
  • English
  • Français

Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation

Published online by Cambridge University Press:  08 May 2018

Caitlin W. Elgarten ,
Staci D. Arnold ,
Yimei Li ,
Yuan-Shung V. Huang ,
Marcie L. Riches ,
Jeffrey S. Gerber ,
Richard Aplenc ,
Wael Saber  and
Brian T. Fisher
Caitlin W. Elgarten*
Affiliation:
Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Staci D. Arnold
Affiliation:
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, Georgia
Yimei Li
Affiliation:
Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Yuan-Shung V. Huang
Affiliation:
Center of Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Marcie L. Riches
Affiliation:
Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Jeffrey S. Gerber
Affiliation:
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Center of Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Division of Infectious Diseases, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Richard Aplenc
Affiliation:
Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Center of Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Wael Saber
Affiliation:
Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin
Brian T. Fisher
Affiliation:
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Center of Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Division of Infectious Diseases, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
*
Address correspondence to Caitlin W. Elgarten, MD, 3501 Civic Center Blvd, Clinical and Translational Research Building, 10th floor, Philadelphia, PA 19104 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To explore the prevalence and drivers of hospital-level variability in antibiotic utilization among hematopoietic cell transplant (HCT) recipients to inform antimicrobial stewardship initiatives.

DESIGN

Retrospective cohort study using data merged from the Pediatric Health Information System and the Center for International Blood and Marrow Transplant Research.

SETTING

The study included 27 transplant centers in freestanding children’s hospitals.

METHODS

The primary outcome was days of broad-spectrum antibiotic use in the interval from day of HCT through neutrophil engraftment. Hospital antibiotic utilization rates were reported as days of therapy (DOTs) per 1,000 neutropenic days. Negative binomial regression was used to estimate hospital utilization rates, adjusting for patient covariates including demographics, transplant characteristics, and severity of illness. To better quantify the magnitude of hospital variation and to explore hospital-level drivers in addition to patient-level drivers of variation, mixed-effects negative binomial models were also constructed.

RESULTS

Adjusted hospital rates of antipseudomonal antibiotic use varied from 436 to 1121 DOTs per 1,000 neutropenic days, and rates of broad-spectrum, gram-positive antibiotic use varied from 153 to 728 DOTs per 1,000 neutropenic days. We detected variability by hospital in choice of antipseudomonal agent (ie, cephalosporins, penicillins, and carbapenems), but gram-positive coverage was primarily driven by vancomycin use. Considerable center-level variability remained even after controlling for additional hospital-level factors. Antibiotic use was not strongly associated with days of significant illness or mortality.

CONCLUSION

Among a homogenous population of children undergoing HCT for acute leukemia, both the quantity and spectrum of antibiotic exposure in the immediate posttransplant period varied widely. Antimicrobial stewardship initiatives can apply these data to optimize the use of antibiotics in transplant patients.

Infect Control Hosp Epidemiol 2018;797–805

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 7 , July 2018 , pp. 797 - 805
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Hicks, LA, Bartoces, MG, Roberts, RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015;60:1308–1316.Google Scholar
2. MacDougall, C, Polk, RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008;29:203–211.Google Scholar
3. Spellberg, B, Guidos, R, Gilbert, D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155–164.Google Scholar
4. Dellit, TH, Owens, RC, McGowan, JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.Google Scholar
5. Gerber, JS, Newland, JG, Coffin, SE, et al. Variability in antibiotic use at children’s hospitals. Pediatrics 2010;126:1067–1073.CrossRefGoogle ScholarPubMed
6. Polk, RE, Hohmann, SF, Medvedev, S, Ibrahim, O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis 2011;53:1100–1110.Google Scholar
7. Kanerva, M, Ollgren, J, Lyytikainen, O, Finnish Prevalence Survey Study Group. Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment. J Antimicrob Chemother 2011;66:2651–2654.Google Scholar
8. Tan, C, Vermeulen, M, Wang, X, Zvonar, R, Garber, G, Daneman, N. Variability in antibiotic use across Ontario acute care hospitals. J Antimicrob Chemother 2017;72:554–563.Google Scholar
9. Kronman, MP, Gerber, JS, Prasad, PA, et al. Variation in antibiotic use for children hospitalized with inflammatory bowel disease exacerbation: a multicenter validation study. J Pediatr Infect Dis Soc 2012;1:306–313.Google Scholar
10. Fisher, BT, Gerber, JS, Leckerman, KH, et al. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia Lymphoma 2013;54:1633–1639.Google Scholar
11. Peled, JU, Jenq, RR, Holler, E, van den Brink, MR. Role of gut flora after bone marrow transplantation. Nat Microbiol 2016;1:16036.Google Scholar
12. Weber, D, Jenq, RR, Peled, JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 2017;23:845–852.Google Scholar
13. Fisher, BT, Sammons, JS, Li, Y, et al. Variation in risk of hospital-onset clostridium difficile infection across beta-lactam antibiotics in children with new-onset acute lymphoblastic leukemia. J Pediatr Infect Dis Soc 2014;3:329–335.Google Scholar
14. Downes, KJ, Cowden, C, Laskin, BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatr 2017;171:e173219.Google Scholar
15. Trifilio, S, Verma, A, Mehta, J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transpl 2004;33:735–739.Google Scholar
16. Whangbo, J, Ritz, J, Bhatt, A. Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2017;52:183–190.Google Scholar
17. Freifeld, AG, Bow, EJ, Sepkowitz, KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56–e93.CrossRefGoogle ScholarPubMed
18. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides. Center for International Blood and Marrow Transplant Research website. https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx. Published 2015. Accessed April 10, 2018.Google Scholar
19. Arnold, SD, Brazauskas, R, He, N, et al. Role of donor source on clinical outcomes and inpatient resource utilization for hematopoietic cell transplantation in children with acute leukemia. Blood 2016;128:1.Google Scholar
20. Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2014.Google Scholar
21. Fridkin, SK, Steward, CD, Edwards, JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.Google Scholar
22. Winestone, LE, Getz, KD, Miller, TP, et al. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. Am J Hematol 2017;92:141–148.Google Scholar
23. Wilkes, JJ, Hennessy, S, Xiao, R, et al. Volume-outcome relationships in pediatric acute lymphoblastic leukemia: association between hospital pediatric and pediatric oncology volume with mortality and intensive care resources during initial therapy. Clin Lymphoma Myeloma Leuk 2016;16:404–410.Google Scholar
24. Getz, KD, Miller, TP, Seif, AE, et al. Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children’s Oncology Group report. Cancer Med 2016;5:2412–2416.Google Scholar
25. Maude, SL, Fitzgerald, JC, Fisher, BT, et al. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med 2014;15:112–120.Google Scholar
26. Wolf, J, Sun, Y, Tang, L, et al. Antimicrobial stewardship barriers and goals in pediatric oncology and bone marrow transplantation: a survey of antimicrobial stewardship practitioners. Infect Control Hosp Epidemiol 2016;37:343–347.Google Scholar
27. Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.CrossRefGoogle Scholar
28. Yeo, CL, Chan, DS, Earnest, A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2012;31:583–590.Google Scholar
29. Azap, A, Topcuoglu, P, Yesilkaya, A, et al. The effect of a nationwide antibiotic restriction policy on antibiotic usage in a stem cell transplantation unit. Turk J Haematol 2005;22:87–90.Google Scholar
30. Saito, T, Yoshioka, S, Iinuma, Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis 2008;27:209–216.Google Scholar
31. Hughes, WT, Armstrong, D, Bodey, GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.CrossRefGoogle ScholarPubMed
32. Taur, Y, Jenq, RR, Perales, MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014;124:1174–1182.Google Scholar
33. Shono, Y, Docampo, MD, Peled, JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Translat Med 2016;8:339ra371–339ra371.Google Scholar
34. Peled, JU, Devlin, SM, Staffas, A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncology 2017;35:1650–1659.Google Scholar
35. Antin, JH. Relationship between intestinal bacteria and the anticancer effect of hematopoietic stem-cell transplantation. J Clin Oncology 2017;35:1636–1637.Google Scholar
36. Staffas, A, Burgos da Silva, M, van den Brink, MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 2017;129:927–933.Google Scholar
37. Grohskopf, LA, Huskins, WC, Sinkowitz-Cochran, RL, et al. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J 2005;24:766–773.Google Scholar
38. Courter, JD, Parker, SK, Thurm, C, et al. Accuracy of administrative data for antimicrobial administration in hospitalized children. J Pediatric Infect Dis Soc 2017. doi: 10.1093/jpids/pix064.Google Scholar
Supplementary material: File

Elgarten et al. supplementary material

Table S1

Download Elgarten et al. supplementary material(File)
File 118.9 KB
Supplementary material: File

Elgarten et al. supplementary material

Table S2

Download Elgarten et al. supplementary material(File)
File 79.2 KB
Supplementary material: File

Elgarten et al. supplementary material

Table S3

Download Elgarten et al. supplementary material(File)
File 93.2 KB